08 September 2020 | News
Growing concerns about the global spread of this respiratory enterovirus
Image source: Shutterstock
Intravacc, a global leader in translational research and development of viral and bacterial vaccines in the Netherlands, announced that it has been awarded a contract with base and options that may total from the US National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), for the development of a prophylactic vaccine against enterovirus D68 (EV D68).
EV D68 is a respiratory virus that can cause childhood paralysis, Acute Flaccid Myelitis (AFM). Intravacc will develop an inactivated EV D68 vaccine, based on Intravacc's proprietary Vero cell technology, from early product selection through to Phase I clinical testing.